These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35257383)

  • 1. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
    Ock M; Lee S; Kim H
    J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
    Habib ZA; Havstad SL; Wells K; Divine G; Pladevall M; Williams LK
    J Clin Endocrinol Metab; 2010 Feb; 95(2):592-600. PubMed ID: 20061432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
    Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
    Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
    van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
    Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
    Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
    Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
    Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
    Schwartz AV; Chen H; Ambrosius WT; Sood A; Josse RG; Bonds DE; Schnall AM; Vittinghoff E; Bauer DC; Banerji MA; Cohen RM; Hamilton BP; Isakova T; Sellmeyer DE; Simmons DL; Shibli-Rahhal A; Williamson JD; Margolis KL
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4059-66. PubMed ID: 26305617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.
    Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
    JAMA Pediatr; 2020 Jun; 174(6):543-551. PubMed ID: 32176276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of fracture with thiazolidinediones: disease or drugs?
    Bazelier MT; Vestergaard P; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2012 Jun; 90(6):450-7. PubMed ID: 22488176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of fractures and diabetes medications: a nationwide cohort study.
    Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
    Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
    Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE
    Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.